Research Area Affiliations
Dr. Welling’s clinical and research interests focus primarily on NF2-associated vestibular schwannomas and the hearing loss, disequilibrium and facial paralysis that may result from the disease. In 1996, Dr. Welling and his collaborators published the promoter of the NF2 gene and documented genotype-phenotype correlations. This work was awarded the Edmund Prince Fowler Award from The Triological Society for the best basic science thesis. Later work using cDNA microarray analysis to identify involved pathways in tumor formation was awarded the Nicholas Torok Award from the American Neurotologic Society. In conjunction with these studies, Dr. Welling leads five targeted clinical trials for NF2-related tumors based upon his in vitro work and the work of many others.
Additional research interests for Dr. Welling include the use of regenerative growth factors for the promotion of healing of tympanic membrane (TM) perforations, as well as the use of virtual simulation in otologic surgery training. The utility of regenerative growth factors in healing TM perforations has been shown in vivo. If found to be successful, the approach could offer an alternative to surgical repair (and greatly reduce associated cost and surgical morbidity). Dr. Welling’s work in the area of otologic surgery training has led to a validated model for temporal bone dissection.
Acoustic neuroma: a cost-effective approach. Welling DB, Glasscock ME, Woods CI, Jackson CG. Otolaryngol HNSurg 1990:103(3):364-370.
Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Welling DB, Guida M, Goll F, Pearl DK, Glasscock ME, Pappas DG, Linthicum FH, Rogers D, Prior TW. Hum Genet 1996:98(2): 189-93.
Clinical manifestions of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas. Welling DB. Laryngoscope 1998: 108(2):178-89.
Analysis of the human neurofibromatosis type 2 gene promoter and its expression. Welling DB, Akhmametyeva EM, Daniels RL, Zhu L, Miles-Markley BA, Chang L-S. Otolaryngol HN Surg 2000; 123: 413-418.
cDNA microarray analysis of vestibular schwannomas. Welling DB, Lasak JM, Akhmametyeva EM, Gaheri B, Chang L-S. Otol Neurotol 2002;23(5): 736-748.
Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up. Neff BA, Wiet RM, Lasak JM, Ramsden R, Cohen N, Welling DB. Laryngoscope 2007;117:1069-1072.
AR42, A Novel Histone Deacetylase Inhibitor, as a Potential Therapy for Vestibular Schwannomas and Meningiomas. Bush ML, Oblinger J, Brendel, V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Chaudhury AR, Kulp S, Chen C-S, Yates C, Chang L-S, Welling DB, Jacob A. Neuro-Oncol 2011; 13:983-989, 2011. PMID: 21778190.
Preclinical Validation of AR42, a Novel Histone Deacetylase Inhibitor, as Treatment for Vestibular Schwannomas. Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, Kulp S, La Perle K, Chen C-S, Chang L-S, Welling DB. Laryngoscope 2012;122(1):174-189.
Virtual temporal bone dissection system: OSU virtual temporal bone system: development and testing. Wiet GJ, Stredney D, Kerwin T, Hittle B, Fernandez SA, Abdel-Rasoul M, Welling DB. Laryngoscope 2012; Mar; 122, suppl 1:S1-12. Epub 2012, January 31.
Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, Chen CS, Jacob A, Welling DB, Chang LS. Cancer Res 2013 Jan 15;73(2):792-803.
View a complete list of publications on pubmed.gov »